Company
Xenon Pharmaceuticals Inc (NASDAQ:XENE)’s 12-Month Price Target Currently Stands At 42
In last trading session, Xenon Pharmaceuticals Inc (NASDAQ:XENE) saw 0.44 million shares changing hands with its beta currently measuring 1.20. Company’s recent per share price
